Loading headlines…

Collected headline brief
US firm ArriVent BioPharma’s shares plummeted after a late-stage trial failure involving a cancer drug licensed from China, a setback that analysts said highlighted the challenges facing Chinese biotech companies expanding overseas. New…
Complete reading on newsGlobal
Full article · 4 min read
AI-generated editorial illustration / newsGlobal. Not a photograph of an actual event.
Read the full article →Full article · 4 min read
AI-generated editorial illustration / newsGlobal. Not a photograph of an actual event.
Read the full article →Full article · 4 min read
AI-generated editorial illustration / newsGlobal. Not a photograph of an actual event.
Read the full article →There is more to this story